Single-Arm, Phase II Proof of Concept Study of IDO-1 Inhibitor Epacadostat in Combination With Pembrolizumab in Advanced Pancreatic Cancer With Chromosomal Instability/ Homologous Recombination Repair Deficiency (HRD)

Trial Profile

Single-Arm, Phase II Proof of Concept Study of IDO-1 Inhibitor Epacadostat in Combination With Pembrolizumab in Advanced Pancreatic Cancer With Chromosomal Instability/ Homologous Recombination Repair Deficiency (HRD)

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 12 Jul 2018

At a glance

  • Drugs Epacadostat (Primary) ; Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 29 Jun 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 11 May 2018 Planned End Date changed from 1 Apr 2021 to 1 Jul 2021.
    • 11 May 2018 Planned primary completion date changed from 1 Apr 2020 to 1 Jul 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top